LANGHORNE, PA--(MARKET WIRE)--Aug 1, 2007 -- Velcera, Inc., a specialty pharmaceutical company focused on pet health, announced today the initiation of pivotal studies evaluating the safety and efficacy of VEL-504, a treatment candidate for canine pain management formulated with Velcera’s PROMIST(TM) delivery system. PROMIST is an FDA-approved, patented, transmucosal delivery system aimed at formulating oral pet treatments into convenient spray-based solutions for enhanced drug bioavailability, faster absorption, and improved treatment compliance. In conjunction with the commencement of pivotal testing, Velcera is shipping PROMIST VEL-504 to twenty five investigational sites in the U.S. and Europe.
